n(1)-methylnicotinamide has been researched along with Neuroendocrine Tumors in 1 studies
N(1)-methylnicotinamide: RN given refers to parent cpd
1-methylnicotinamide : A pyridinium ion comprising nicotinamide having a methyl group at the 1-position. It is a metabolite of nicotinamide which was initially considered to be biologically inactive but has emerged as an anti-thrombotic and anti-inflammatory agent.
Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouma, G | 1 |
| van Faassen, M | 1 |
| Kats-Ugurlu, G | 1 |
| de Vries, EG | 1 |
| Kema, IP | 1 |
| Walenkamp, AM | 1 |
1 other study available for n(1)-methylnicotinamide and Neuroendocrine Tumors
| Article | Year |
|---|---|
Niacin (Vitamin B3) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Neuroendocr | 2016 |